Glyphosate mustard tablets

This product is a glycine phosphoryl nitrogen mustard compound, which is a cyclophosphamide derivative, but does not require activation and can directly play an alkylating role. Its mechanism of action is mainly to inhibit DNA synthesis. Animal experiments show that the tumor inhibition rates for Yoshida sarcoma solid type and ascites type are 99.7% and 100% respectively, Wacker carcinosarcoma 256 is 91%, sarcoma S180 is 30%, reticular cell sarcoma L2 is 30%, and spindle cell sarcoma B22 is 45%. In tissue culture, it has a significant inhibitory effect on the proliferation and mitosis of Hela cells. In animal subacute toxicity experiments, dogs were given 20 mg/kg of glyphosate mustard daily for 10 consecutive days. There was no significant effect on red blood cells, hemoglobin, liver and kidney function, and no obvious gastrointestinal reaction. However, the inhibition of white blood cells and platelets has occurred, but it can return to normal after 2 days of drug withdrawal.

Glyphosate mustard

This product is white tablets.

Currently, it is mainly used topically to treat cancerous ulcers such as breast cancer and cervical cancer.

Intermittent oral administration: 0.5g each time, twice a day, for 4 consecutive days a week, rest for 3 days, total amount 20g for one course of treatment. Continuous oral administration: 0.5g each time, twice a day, continuous use, total amount 15-20g for one course of treatment. With the emergence of a large number of new anticancer drugs, this drug is rarely used orally. Mainly used for local medication: spray with 20% dimethyl sulfoxide solution of glyphosate mustard, or apply 1%-2% silicic acid ointment topically on the ulcer surface, twice a day, for 20-30 days as one course of treatment.

Gastrointestinal reactions: loss of appetite, nausea and vomiting, but the degree is relatively mild. Oral medication mainly causes bone marrow suppression: manifested as leukopenia and thrombocytopenia, which often occurs in the later stage of medication and has little effect on hemoglobin. The hemoglobin decrease rate of intermittent medication and continuous medication was 4.2% and 7.7% respectively, leukopenia was 22.2% and 46.2% respectively, and thrombocytopenia was 25.4% and 23.1% respectively. Other reactions include mild dizziness, fatigue, etc.

It is contraindicated for patients with severe bone marrow suppression, infection, or allergic reaction to this product.

Not yet clear

Keep in a dark place, tightly sealed and store below 25℃.

0.1g

Jilin Jiatai Pharmaceutical Co., Ltd.

• Founded in:

  2014-03-11

• Address:

  No. 8, Yongkang Road, Chaoyang Town, Huinan County, Jilin Province

• Tax NO.:

  912205233078719518

• Registered Funds:

  50 million yuan

• Email:

  Log in to view